|Articles|January 27, 2021

SARS-CoV-2 Reacts to 2003 SARS Virus Antibodies

Author(s)Killian Meara

The findings may have important implications on vaccine research and development.

Investigators from the Oregon Health & Science University have discovered that antibodies generated from the coronavirus disease 2019 (COVID-19) react to strains from other coronaviruses, including those from the SARS outbreak that occurred in 2003. The study was published in the journal Cell Reports.

"Our finding has some important implications concerning immunity toward different strains of coronavirus infections, especially as these viruses continue to mutate," Tafesse said.

The investigators were not surprised to see that antibodies generated from a virus from almost 2 decades ago provided a defense, however small it was, due to the fact that estimated mutations occur 1 to 2 times per month. They indicated that further research needs to be done to determine the lasting efficacy of COVID-19 vaccines.

"I don't think there is any one size-fits-all vaccine," Fikadu Tafesse, senior author on the study and assistant professor of molecular biology and immunology at the OHSU School of Medicine said. "Although the vaccines coming out now may break the momentum of the virus and end the pandemic, they may not be the end game."

Additional findings from the study may suggest that since antibodies in the blood can potentially react to those of other strains of coronaviruses, that the efforts to accurately discern a previous COVID-19 infection may be more difficult. While this may complicate the diagnosis of the disease, knowing how the SARS-CoV-2 virus reacts to antibodies of multiple strains may actually afford the expansion of abilities to study its underlying biology and causal effects.

"I'm not personally terribly concerned. Emerging mutant viruses may have some propensity to escape certain antibodies raised by previous infection or vaccine,” Timothy Bates, lead author on the study said. "Every individual has a different immune system that will make a unique repertoire of different antibodies that bind to different places on the virus, so the chance of any one SARS-CoV-2 variant escaping from all of them is quite low."


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.